Renalytix plc Reports Net Loss of $46.2 Million for the Year Ended June 30, 2023

Renalytix plc [RNLX], a leading healthcare c ompany specializing in kidney disease diagnostics and solutions, has released its consolidated income statement for the fiscal year ending June 30, 2023. The report reveals a net loss of $46.2 million for the year, but the company managed to achieve revenue of $3.4 million despite facing various challenges.

Revenue Shows Growth

Renalytix plc reported total revenue of $3.4 million for the fiscal year ending June 30, 2023. This marks a significant increase from the previous year's revenue of $2.97 million. The positive growth in revenue demonstrates the company's ability to generate income even in challenging conditions.

Operating Loss and Expenses